Business, energy, technology, markets and global industry news from Business News Today

FDA

PharmaDeviceNews FDA
Representative image of a patient using a portable ECG device during a remote cardiac consultation, illustrating how HeartBeam’s technology could move heart attack risk assessment closer to the patient.
Medical Devices & Diagnostics

HeartBeam’s peer-reviewed ECG data raises the stakes in remote cardiac diagnostics

HeartBeam’s ECG evidence could push chest pain assessment closer to patients. The next test is FDA clarity and clinical trust.

Read More
Pharma & Biotech

Why Hansa Biopharma’s ConfIdeS trial could reshape kidney transplant desensitization

Hansa Biopharma’s imlifidase faces a decisive FDA year as Phase 3 transplant data test whether desensitization can unlock donor access.

Read More
Representative image: A cancer patient receives infusion-based oncology care in a modern clinic, reflecting Datroway’s FDA approval as a new first-line treatment option for metastatic triple-negative breast cancer patients who are not eligible for immunotherapy.
Pharma & Biotech

AstraZeneca and Daiichi Sankyo deepen ADC ambitions with Datroway’s TNBC approval

Datroway challenges chemotherapy in first-line TNBC. AstraZeneca and Daiichi Sankyo now face the real test: adoption, safety and access.

Read More
Pharma & Biotech

Can Leads Biolabs turn Opamtistomig into a frontline EP-NEC treatment contender?

EP-NEC has no approved drug worldwide. Leads Biolabs now has to prove Opamtistomig can turn rare-tumor urgency into regulatory momentum.

Read More
Representative image: A clinician examines a minimally invasive urology device in a medical lab, reflecting Butterfly Medical’s $21 million funding push to advance its BPH treatment technology for benign prostatic hyperplasia.
Medical Devices & Diagnostics

Is Butterfly Medical’s prostate retraction device the next challenger in minimally invasive BPH treatment?

BPH care needs options beyond pills and surgery. Butterfly Medical’s $21m raise puts its reversible prostate implant in the spotlight.

Read More
Representative image: A clinician reviews a cloud-based insulin dosing dashboard in a hospital setting, reflecting how Glooko’s FDA-cleared EndoTool IV Cloud could support inpatient diabetes management, intravenous insulin dosing, and safer glycemic control workflows.
Medical Devices & Diagnostics

Why Glooko’s FDA-cleared EndoTool IV Cloud could reshape hospital glycemic management

Insulin dosing is moving to the cloud. Glooko’s FDA clearance raises bigger questions on hospital workflow, safety, and scale.

Read More
Representative image: AI-enabled real-world evidence analysis in a diagnostics laboratory highlights how OM1’s 650,000-patient study supported FDA approval of Hologic’s Aptima HPV Assay for primary cervical cancer screening.
Medical Devices & Diagnostics

Did OM1 just prove AI-powered real-world evidence can survive FDA scrutiny?

FDA-grade evidence is getting bigger and harder to collect. OM1’s Hologic study shows how AI may change medtech submissions.

Read More
Representative image: A subcutaneous Alzheimer’s treatment injector is shown in a clinical consultation setting as Eisai Co., Ltd. and Biogen Inc. await the FDA’s August 2026 decision on Leqembi Iqlik as a starting dose for early Alzheimer’s disease.
Pharma & Biotech

FDA review extension keeps Eisai and Biogen waiting on Leqembi Iqlik starting-dose strategy

Alzheimer’s drugs need easier delivery. Eisai and Biogen now face an FDA timing test that could shape Leqembi’s access story.

Read More
Representative image: Novo Nordisk’s Wegovy pill launch in the U.S. obesity drug market is illustrated through unbranded tablets, prescription growth data and healthcare market signals, reflecting rising demand for oral GLP-1 weight-loss treatments.
Pharma & Biotech

Can Novo Nordisk’s Wegovy pill reshape the obesity market before Eli Lilly catches up?

Novo Nordisk has the first-mover pill. Eli Lilly has the growth aura. Oral obesity drugs are turning access into the next GLP-1 battleground.

Read More
Representative image: AstraZeneca’s TRUQAP prostate cancer push highlights the growing role of targeted therapy and PTEN testing in metastatic hormone-sensitive prostate cancer treatment.
Pharma & Biotech

Why AstraZeneca’s TRUQAP ODAC vote could reshape PTEN-deficient prostate cancer treatment

TRUQAP has ODAC support, but toxicity and survival maturity still matter. AstraZeneca’s prostate cancer expansion now faces FDA’s final test.

Read More